Longeveron
- Laromestrocel DCM Ph2/3 start2H 2026Laromestrocel DCM Ph2/3 start, 2H 2026, routine
- Company strategic review4Q 2026Company strategic review, 4Q 2026, routine
- Laromestrocel HLHS BLA filing2027Laromestrocel HLHS BLA filing, 2027, material
- Pediatric DCM Phase 2 registrational2027Pediatric DCM Phase 2 registrational, 2027, routine
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (4 active programs)
Biotech Distilled coverage (13)
- 2026-09-17 UPDATE: Longeveron (LGVN) - The Envelope Opened and It Was Empty 🔒 Paid
- 2026-08-24 UPDATE: Longeveron (LGVN) - They Spent the Bullet Before the Data
- 2026-08-13 UPDATE: Longeveron (LGVN) - Four Weeks of Oxygen Left
- 2026-05-14 UPDATE: Longeveron (LGVN) - The ATM Trap Snaps Shut
- 2026-05-09 UPDATE: Longeveron (LGVN) - The FDA Pulls the Pivotal Rug 🔒 Paid
- 2026-03-21 UPDATE: Longeveron (LGVN) - The 10-K Autopsy 🔒 Paid
- 2026-03-15 UPDATE: Longeveron (LGVN) - Surviving the Gap (But Pawning the Crown Jewel) 🔒 Paid
- 2026-03-07 UPDATE: Longeveron (LGVN) - The Reverse Stock Split and the Dilution Trap 🔒 Paid
- 2026-02-28 UPDATE: Longeveron (LGVN) - Scientific Validation vs. Financial Reality 🔒 Paid
- 2026-02-14 UPDATE: Longeveron (LVGN) - The Financial Fire Alarm is Ringing 🔒 Paid
- 2026-02-07 UPDATE : Longeveron (LGVN) - Rare Pediatric Disease PRV Program Reauthorized 🔒 Paid
- 2026-01-30 UPDATE: Longeveron (LGVN) - Regulatory Momentum & Manufacturing Moat 🔒 Paid
- 2026-01-06 Longeveron Inc (LGVN): Scientific Deep Dive for Lead and Pipeline Products
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.